Video -

2012 BPI Europe Conference Review

Reasons why BPI Europe remains the leading bioprocessing event in Europe
  • License: © All rights reserved
    The Content may only be used by Mynewsdesk. It is thus not permissible for anyone else to download, copy, distribute or otherwise use the Content (other than for private use to the extent permitted by law).
  • File format: .mov
  • Length: 1:11

Topics

  • Engineering industry

Categories

  • bioprocess international magazine
  • bioprocess international conference & exhibition
  • bpi
  • bioprocess
  • bpi europe
  • cell culture
  • antibody drug conjugates
  • bioproduction
  • downstream processing in biopharmaceuticals
  • networking
  • partnering activities
  • single use
  • cell line identification
  • cell line engineering

Contacts

Daniel Barry

Press contact Dr BPI Europe Project Manager

Related content

Europe's Leading Meeting for Bioprocessing Announces Biosimilars, Antibody Drug Conjugates and New Processing Technologies as Key Themes for 2013

The pursuit of Biosimilars, Antibody-Drug Conjugates and New Processing Technologies will set the trend for biomanufacturing in 2013; so says research from the industry's leading conference and exhibition, BioProcess International Europe.

Deal making in the biosimilars market: increasing investment for decreasing return? - DataMonitor

Biosimilars are big business. The global biologics market reached $125 billion in 2011, and is predicted to top $150 billion by the end of 2016. Of this, roughly $60 billion will be in off-patent sales.

ADC manufacturing made rapid progress over last five years, says Seattle Genetics

Exclusive Interview with Nathan Ihle, Executive Director, Process Chemistry & Analytical Biochemistry, Seattle Genetics, USA

Peter Greenleaf steps down as MedImmune president, Bahija Jallal chosen as replacement

Peter Greenleaf is stepping down down as president of Gaithersburg-based biotechnology giant MedImmune, according to a company spokesman, to take the helm of parent company AstraZeneca’s Latin America business.
He will be replaced by Bahija Jallal, who currently serves as MedImmune’s executive vice president of research and development. Jallal joined the company in 2006 as vice president of tra

Cell Culture Becomes an Integral Part of Cell Line Development and Engineering

Market demands to reduce manufacturing costs require better Cell culture processes

Pfizer Will Evaluate Whether to Divide Drug Units, CEO Read Says Drew Armstrong - ©2013 Bloomberg News

Jan. 30 (Bloomberg) -- Pfizer Inc., the world’s largest drugmaker, may consider dividing its branded medicines and generic products units into separate businesses, Chief Executive Officer Ian Read said.

Lonza pins future hopes on ADC manufacturing

ZURICH, Jan 24 (Reuters) - Swiss specialty chemicals and life sciences group Lonza reported a better than expected rise in profits on Thursday but dampened expectations of another big jump this year, taking the edge off a two-month rally in the share price.

Sartorius Profits Jump 20% driven by growth in bioprocessing

Sartorius said today it finished last year with a 20% jump in profits, helped by growing U.S. revenue as well as growth in its bioprocessing, industrial weighing, and lab products and services units.

Sanofi’s Chief Says Investors Underestimate Drug Pipeline - Originally Published in Bloomberg

Sanofi (SAN) Chief Executive Officer Chris Viehbacher says investors are still underestimating the French company’s pipeline of experimental drugs.